Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.
The study, sponsored by University Hospital, Clermont-Ferrand, investigates the effects of two established acetylcholinesterase inhibitors, Galantamine and Donepezil, on sleep quality in Alzheimer's patients aged 65 and older. Given the increasing prevalence of Alzheimer's disease and associated sleep disturbances, this research could provide valuable insights into adjunctive therapies that improve patient quality of life. The collaboration with Janssen-Cilag indicates potential industry interest, which may enhance the commercial viability of findings. The market for Alzheimer's therapies is significant, with a growing demand for treatments that address comorbid conditions such as sleep disorders. However, the competitive landscape includes numerous existing therapies, necessitating a clear differentiation of benefits from this study.
Indication: Alzheimer's Disease
Modality: small molecule
Target: Acetylcholinesterase (Ach-E) inhibitors: Galantamine and Donepezil
Sponsor: University Hospital, Clermont-Ferrand
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Acetylcholinesterase (Ach-E) inhibitors: Galantamine and Donepezil
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Acetylcholinesterase (Ach-E) inhibitors: Galantamine and Donepezil
Target normalized: Acetylcholinesterase (Ach-E) inhibitors: Galantamine and Donepezil